miR-122 continues to blaze the trail for microRNA therapeutics.
作者信息
Haussecker Dirk, Kay Mark A
机构信息
Department of Pediatrics and Genetics, Stanford University, Stanford, California, USA.
出版信息
Mol Ther. 2010 Feb;18(2):240-2. doi: 10.1038/mt.2009.313.
Abstract
摘要
相似文献
1
miR-122 continues to blaze the trail for microRNA therapeutics.
Mol Ther. 2010 Feb;18(2):240-2. doi: 10.1038/mt.2009.313.
2
Engineered microRNA therapeutics.
J R Coll Physicians Edinb. 2014;44(3):196-200. doi: 10.4997/JRCPE.2014.302.
3
MicroRNAs and hepatitis C virus: toward the end of miR-122 supremacy.
Virol J. 2012 Jun 12;9:109. doi: 10.1186/1743-422X-9-109.
4
Targeting microRNA-122: walking on cutting edge of hepatitis C virus infection therapy.
Acta Virol. 2014;58(4):301-8. doi: 10.4149/av_2014_04_301.
5
The biology of hepatitis C virus infection. Lessons learned from chimpanzees.
Curr Stud Hematol Blood Transfus. 1994(61):195-207. doi: 10.1159/000423276.
6
Characterization of hepatitis C virus infectious clones in chimpanzees: long-term studies.
Curr Top Microbiol Immunol. 2000;242:279-98. doi: 10.1007/978-3-642-59605-6_13.
7
Kinetics of miR-122 expression in the liver during acute HCV infection.
PLoS One. 2013 Oct 4;8(10):e76501. doi: 10.1371/journal.pone.0076501. eCollection 2013.
8
Prospects for a vaccine against the hepatitis C virus.
Nature. 2005 Aug 18;436(7053):961-6. doi: 10.1038/nature04081.
9
microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection.
PLoS One. 2013 Oct 9;8(10):e76867. doi: 10.1371/journal.pone.0076867. eCollection 2013.
10
Impact of microRNAs for pathogenesis and treatment of hepatitis C virus infection.
Gastroenterol Clin Biol. 2010 Sep;34(8-9):431-5. doi: 10.1016/j.gcb.2010.04.010. Epub 2010 Jun 2.
引用本文的文献
1
The circRNA circVAMP3 restricts influenza A virus replication by interfering with NP and NS1 proteins.
PLoS Pathog. 2023 Aug 21;19(8):e1011577. doi: 10.1371/journal.ppat.1011577. eCollection 2023 Aug.
2
Emerging Role of Interferon-Induced Noncoding RNA in Innate Antiviral Immunity.
Viruses. 2022 Nov 23;14(12):2607. doi: 10.3390/v14122607.
3
Crosstalk between Environmental Inflammatory Stimuli and Non-Coding RNA in Cancer Occurrence and Development.
Cancers (Basel). 2021 Sep 2;13(17):4436. doi: 10.3390/cancers13174436.
4
The versatile nature of miR-9/9 in human cancer.
Oncotarget. 2018 Apr 17;9(29):20838-20854. doi: 10.18632/oncotarget.24889.
5
Resolving Subcellular miRNA Trafficking and Turnover at Single-Molecule Resolution.
Cell Rep. 2017 Apr 18;19(3):630-642. doi: 10.1016/j.celrep.2017.03.075.
6
Interferon Control of the Sterol Metabolic Network: Bidirectional Molecular Circuitry-Mediating Host Protection.
Front Immunol. 2016 Dec 23;7:634. doi: 10.3389/fimmu.2016.00634. eCollection 2016.
7
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.
Oral Oncol. 2016 May;56:32-9. doi: 10.1016/j.oraloncology.2016.02.015. Epub 2016 Mar 19.
8
Heterogeneous Ribonucleoprotein K (hnRNP K) Binds miR-122, a Mature Liver-Specific MicroRNA Required for Hepatitis C Virus Replication.
Mol Cell Proteomics. 2015 Nov;14(11):2878-86. doi: 10.1074/mcp.M115.050344. Epub 2015 Sep 1.
9
Outside the coding genome, mammalian microRNAs confer structural and functional complexity.
Sci Signal. 2015 Mar 17;8(368):re2. doi: 10.1126/scisignal.2005813.
10
MicroRNAs: The Missing Link in the Biology of Graft-Versus-Host Disease?
Front Immunol. 2013 Dec 2;4:420. doi: 10.3389/fimmu.2013.00420.
本文引用的文献
1
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.
Science. 2010 Jan 8;327(5962):198-201. doi: 10.1126/science.1178178. Epub 2009 Dec 3.
2
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.
J Biol Chem. 2009 Nov 13;284(46):32015-27. doi: 10.1074/jbc.M109.016774. Epub 2009 Sep 2.
3
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties.
Oncogene. 2009 Oct 8;28(40):3526-36. doi: 10.1038/onc.2009.211. Epub 2009 Jul 20.
4
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
N Engl J Med. 2009 Apr 30;360(18):1839-50. doi: 10.1056/NEJMoa0807650.
5
LNA-mediated microRNA silencing in non-human primates.
Nature. 2008 Apr 17;452(7189):896-9. doi: 10.1038/nature06783. Epub 2008 Mar 26.
6
Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
Antimicrob Agents Chemother. 2007 Dec;51(12):4290-6. doi: 10.1128/AAC.00723-07. Epub 2007 Oct 1.
7
Therapeutic application of RNA interference for hepatitis C virus.
Adv Drug Deliv Rev. 2007 Oct 10;59(12):1263-76. doi: 10.1016/j.addr.2007.03.022. Epub 2007 Aug 11.
8
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.
RNA Biol. 2004 Jul;1(2):106-13. doi: 10.4161/rna.1.2.1066. Epub 2004 Jul 1.
9
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.
Cell Metab. 2006 Feb;3(2):87-98. doi: 10.1016/j.cmet.2006.01.005.
10
Silencing of microRNAs in vivo with 'antagomirs'.
Nature. 2005 Dec 1;438(7068):685-9. doi: 10.1038/nature04303. Epub 2005 Oct 30.
Zotero 插件